Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Tables)

3 Months Ended

Oct. 31, 2019

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended October 31, 2019	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues	$	12,780		$	7,427			—			—		$	20,207

Operating costs and expenses:
Cost of revenues		10,975			3,546			—			—			14,521
Research and development		350			516		$	188			—			1,054
Selling, general and administrative		6,215			2,757			—		$	2,167			11,139
Legal and related expenses		50						—			1,646			1,696
Total operating costs and expenses		17,590			6,819			188			3,813			28,410

Operating income (loss)		(4,810	)		608			(188	)		(3,813	)		(8,203	)

Other income (expense):
Interest		(12	)		18			—			231			237
Other		3			(12	)		—			136			127
Foreign exchange loss		—			191			—			—			191
Income (loss) before income taxes	$	(4,819	)	$	805		$	(188	)	$	(3,446	)	$	(7,648	)

Depreciation and amortization included above	$	409		$	251		$	—		$	65		$	725

Share-based compensation included in above:
Selling, general and administrative		34			22			—			163			219
Total	$	34		$	22		$	—		$	163		$	219

Capital expenditures	$	147		$	127		$	—		$	—		$	274

Three months ended October 31, 2018	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues	$	14,297		$	6,963			—			—		$	21,260

Operating costs and expenses:
Cost of revenues		10,968			3,271			—			—			14,239
Research and development		—			507		$	221			—			728
Selling, general and administrative		6,060			2,924			—		$	1,986			10,970
Legal and related expenses		36			7			—			1,258			1,301
Total operating costs and expenses		17,064			6,709			221			3,244			27,238

Operating income (loss)		(2,767	)		254			(221	)		(3,244	)		(5,978	)

Other income (expense):
Interest		(18	)		16			—			276			274
Other		40			4			—			3			47
Foreign exchange loss		—			(324	)		—			—			(324	)
Loss before income taxes	$	(2,745	)	$	(50	)	$	(221	)	$	(2,965	)	$	(5,981	)

Depreciation and amortization included above	$	403		$	342		$	—		$	21		$	766

Share-based compensation included in above:
Selling, general and administrative		38		$	24			—		$	173			235
Total	$	38		$	24		$	—		$	173		$	235

Capital expenditures	$	354		$	52		$	—		$	—		$	406